We are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is driving the development of new targeted therapies, coupled with advances in sequencing technology capability.
In the latest version release of COSMIC (v85) there are now 719 cancer-associated genes listed in the Cancer Gene Census, and in 2017 35% of the new molecular entities (NMEs) approved by the FDA were precision medicines. As a result, we are seeing larger and more complex gene panels being designed by assay developers to support the clinical community in testing for actionable mutations in these genes. This now includes more challenging variant types such as CNVs, INDELs and gene fusions.
Any new NGS assays coming to market need to be properly validated before they can be used for patient testing, as errors can occur in sample handling, library prep, sequencing and bioinformatics analysis – which can lead to inaccurate test results. Horizon offers a wide range of reference standards to support the validation of NGS sequencing assays, from development to routine quality monitoring.
In this webinar, we will discuss the requirements for assay validation, how to select the correct reference standard, frequent challenges and best practices.
Speaker: Hannah Child, Product Manager - Horizon Discovery
You can search through our broad range of Reference Standards by: